Taysha Gene Therapies (TSHA) Common Equity: 2022-2025
Historic Common Equity for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $219.0 million.
- Taysha Gene Therapies' Common Equity rose 146.62% to $219.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.0 million, marking a year-over-year increase of 146.62%. This contributed to the annual value of $71.5 million for FY2024, which is 4.55% down from last year.
- According to the latest figures from Q3 2025, Taysha Gene Therapies' Common Equity is $219.0 million, which was down 11.96% from $248.7 million recorded in Q2 2025.
- Taysha Gene Therapies' Common Equity's 5-year high stood at $248.7 million during Q2 2025, with a 5-year trough of -$49.1 million in Q3 2023.
- In the last 3 years, Taysha Gene Therapies' Common Equity had a median value of $71.5 million in 2024 and averaged $74.5 million.
- Over the last 5 years, Taysha Gene Therapies' Common Equity had its largest YoY gain of 7,796.42% in 2023, and its largest YoY loss of 558.88% in 2023.
- Over the past 4 years, Taysha Gene Therapies' Common Equity (Quarterly) stood at $949,000 in 2022, then surged by 7,796.42% to $74.9 million in 2023, then declined by 4.55% to $71.5 million in 2024, then spiked by 146.62% to $219.0 million in 2025.
- Its Common Equity was $219.0 million in Q3 2025, compared to $248.7 million in Q2 2025 and $55.1 million in Q1 2025.